Evidence map›Paper›PMID 30975015›Full record

ArticleCancer biology & therapy2019

Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.

Dexing Wang, Guowei Qian, Jin Wang, Tian Wang, Lian Zhang, Ping Yang, Feng Lin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dexing Wanga Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Guowei Qiana Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Jin Wanga Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Tian Wanga Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Lian Zhanga Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Ping Yanga Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Feng Lina Department of the Medical Oncology , The Eighth People's Hospital of Shanghai , Shanghai , P.R. China.
Shanghai Eighth People Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the mechanisms of chemoresistance in osteosarcoma (OS) cell is important for drug development. By establishment of cisplatin (CDDP) resistant OS cells, we found that the levels of visfatin in OS/CDDP cells were significantly greater than that in their parental cells. The CDDP resistant OS cells showed greater migration and invasion capability than that of parental cells. Knockdown of visfatin can rescue the CDDP sensitivity of resistant OS cells. Among the detected epithelial-mesenchymal transition-related transcription factors (EMT-TFs), visfatin can increase the expression of Snail and Zeb-1 in OS cells. Overexpression of Snail and Zeb1 can attenuate si-visfatin reduced CDDP resistance of OS cells. Mechanistical studies indicated that visfatin can increase the mRNA expression of Snail and therefore upregulate its expression via HIF-1α induced transcription. As to Zeb1, visfatin had no effect on its mRNA expression, while significantly increased its protein stability. Furthermore, the upregulation of ATM, which can phosphorylate and stabilize Zeb1, was involved in visfatin-induced Zeb1 expression in OS cells. Collectively, our revealed that visfatin was involved in CDDP resistance of OS cells via upregulation of Snail and Zeb1, suggesting that inhibition of visfatin might be a potential pathway for OS treatment.

Indexed as

Cell Line, TumorCell MovementCell ProliferationCisplatinCytokinesDose-Response Relationship, DrugDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitModels, BiologicalNicotinamide PhosphoribosyltransferaseOsteosarcomaSnail Family Transcription FactorsZinc Finger E-box-Binding Homeobox 1CisplatinCytokinesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanSnail Family Transcription FactorsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1CDDP resistanceosteosarcomaSnailVisfatinZeb1

Identifiers

PMID30975015
PMCPMC6605995
OpenAlexW2937931166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.